References
- Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts . Female breast cancer. National Cancer Institute, MD, USA (2019). https://seer.cancer.gov/statfacts/html/breast.html
- Mariotto AB , EtzioniR, HurlbertM, PenberthyL, MayerM. Estimation of the number of women living with metastatic breast cancer in the United States.Cancer Epidemiol. Biomarkers Prev.26, 809–815 (2017).
- Miller KD , SiegelRL, LinCCet al. Cancer treatment and survivorship statistics, 2016.CA Cancer J. Clin.66, 271–289 (2016).
- Howlader N , AltekruseSF, LiCIet al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.J. Natl Cancer Inst.106(5), doi: 10.1093/jnci/dju055 (2014).
- Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts . Female breast cancer subtypes. National Cancer Institute, MD, USA (2019). https://seer.cancer.gov/statfacts/html/breast-subtypes.html
- Pfizer . Ibrance (palbociclib) online material (2019). https://www.pfizerpro.com/product/ibrance?cbn=1-510216238:1-518669114#ref3
- Princic N , AizerA, TangDH, SmithDM, JohnsonW, BardiaA. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.Curr. Med. Res. Opin35(1), 73–80 (2018).
- Gennari A , StocklerM, PuntoniMet al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J. Clin. Oncol.29, 2144–2149 (2011).
- NCCN . NCCN Clinical Practice Guidelines in Oncology – breast cancer (NCCN Evidence Blocks), version 1.2018 (2018). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf
- Xi J , OzaA, ThomasSet al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer.J. Natl Compr. Canc. Netw.17, 141–147 (2019).
- Cortes J , O’ShaughnessyJ, LoeschDet al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase III open-label randomised study.Lancet377, 914–923 (2011).
- Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur. J. Cancer45, 228–247 (2009).
- Feinberg BA , BharmalM, KlinkAJ, NabhanC, PhatakH. Using response evaluation criteria in solid tumors in real-world evidence cancer research.Future Oncol.14, 2841–2848 (2018).
- Luke JJ , GhateSR, KishJet al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.Future Oncol.15(25), 2933–2942 (2019).
- Gamucci T , MichelottiA, PizzutiLet al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.J. Cancer5, 320–327 (2014).
- Pedersini R , VassalliL, ClapsMet al. Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study.Oncology94(Suppl. 1), 10–15 (2018).
- Tanaka T , UenoM, NakashimaYet al. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.Thorac. Cancer8, 523–529 (2017).
- Campigotto F , WllerE. Impact of informative censoring on the Kaplan–Meier estimate of progression-free survival in Phase II clinical trials.J. Clin. Oncol.32, 3068–3074 (2014).
- Kaufman PA , AwadaA, TwelvesCet al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.J. Clin. Oncol.33, 594–601 (2015).
- Eggersmann TK , DegenhardtT, GluzO, WuerstleinR, HarbeckN. CDK4/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib.BioDrugs33, 125–135 (2019).